retatrutide type 2 diabetes trial results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 New Kind of Diabetes Drug

For the forty-three percent planning to offer coverage next year, we recommend a physician-led approach that guides who should be prescribed GLP-1 medications and how to make them part of a holistic health management plan." Survey Key Findings Trusted information and cost are barriers The main obstacles to incorporating GLP-1 medications are lack of trusted information and the perceived high cost associated with them

Postgrad Med J 96(1133):156161 Singh K, Aulakh SK, Nijjar GS, Singh S, Sandhu APS, Luthra S, et al (2024) Rebalancing the gut: glucagon-like peptide-1 agonists as a strategy for obesity and metabolic health

That means it hits three gut hormones, not just one or two

However, other in vitro research using human liver microsomes shows that gymnema does not affect CYP3A4 activity

Why are the patches becoming so popular